Compare Novartis AG (NVS) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Koninklijke Philips NV — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Koninklijke Philips NV trades at $27.09 (market cap $26.33B). The key difference: Novartis AG is far larger — about 11.3× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| NVS | PHG | |
|---|---|---|
Market Cap | $298.18B | $26.33B |
Sector | Health | Health |
52-Week High | $168.62 | $32.91 |
52-Week Low | $119.31 | $25.02 |
Enterprise Value | $339.50B | $32.89B |
Dividend Yield | 3.02% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
PHG trades at $26.73, up 1.52% today, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The company reported $17.83B revenue and $895M net income for 2025, with a P/E of 20.29 and net margin of 6.31%. Recent news highlights Exor increasing its stake and FDA clearances for new health tech products, supporting positive sentiment.
Outlook is cautiously optimistic with strong profitability and institutional interest, but risks include order intake volatility and debt levels. Analysts show 40.9% buy ratings, indicating potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
